key: cord-304746-7yzybukk
authors: Li, Xinye; Pan, Xiandu; Li, Yanda; An, Na; Xing, Yanfen; Yang, Fan; Tian, Li; Sun, Jiahao; Gao, Yonghong; Shang, Hongcai; Xing, Yanwei
title: Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review
date: 2020-07-28
journal: Crit Care
DOI: 10.1186/s13054-020-03183-z
sha: 
doc_id: 304746
cord_uid: 7yzybukk

BACKGROUND: Cardiac injury is now a common complication of coronavirus disease (COVID-19), but it remains unclear whether cardiac injury-related biomarkers can be independent predictors of mortality and severe disease development or intensive care unit (ICU) admission. METHODS: Two investigators searched the PubMed, EMBASE, Cochrane Library, MEDLINE, Chinese National Knowledge Infrastructure (CNKI), Wanfang, MedRxiv, and ChinaXiv databases for articles published through March 30, 2020. Retrospective studies assessing the relationship between the prognosis of COVID-19 patients and levels of troponin I (TnI) and other cardiac injury biomarkers (creatine kinase [CK], CK myocardial band [CK-MB], lactate dehydrogenase [LDH], and interleukin-6 [IL-6]) were included. The data were extracted independently by two investigators. RESULTS: The analysis included 23 studies with 4631 total individuals. The proportions of severe disease, ICU admission, or death among patients with non-elevated TnI (or troponin T [TnT]), and those with elevated TnI (or TnT) were 12.0% and 64.5%, 11.8% and 56.0%, and 8.2% and. 59.3%, respectively. Patients with elevated TnI levels had significantly higher risks of severe disease, ICU admission, and death (RR 5.57, 95% CI 3.04 to 10.22, P < 0.001; RR 6.20, 95% CI 2.52 to 15.29, P < 0.001; RR 5.64, 95% CI 2.69 to 11.83, P < 0.001). Patients with an elevated CK level were at significantly increased risk of severe disease or ICU admission (RR 1.98, 95% CI 1.50 to 2.61, P < 0.001). Patients with elevated CK-MB levels were at a higher risk of developing severe disease or requiring ICU admission (RR 3.24, 95% CI 1.66 to 6.34, P = 0.001). Patients with newly occurring arrhythmias were at higher risk of developing severe disease or requiring ICU admission (RR 13.09, 95% CI 7.00 to 24.47, P < 0.001). An elevated IL-6 level was associated with a higher risk of developing severe disease, requiring ICU admission, or death. CONCLUSIONS: COVID-19 patients with elevated TnI levels are at significantly higher risk of severe disease, ICU admission, and death. Elevated CK, CK-MB, LDH, and IL-6 levels and emerging arrhythmia are associated with the development of severe disease and need for ICU admission, and the mortality is significantly higher in patients with elevated LDH and IL-6 levels. GRAPHICAL ABSTRACT: [Image: see text]

Conclusions: COVID-19 patients with elevated TnI levels are at significantly higher risk of severe disease, ICU admission, and death. Elevated CK, CK-MB, LDH, and IL-6 levels and emerging arrhythmia are associated with the development of severe disease and need for ICU admission, and the mortality is significantly higher in patients with elevated LDH and IL-6 levels.

Keywords: Cardiac injury, Biomarkers, COVID-19, Meta-analysis, Mortality

Coronavirus disease (COVID-19) has spread worldwide, becoming a public health and medical care challenge in many countries. As of April 25, 2020, COVID-19 had spread to 213 countries, areas or territories, with 2,719, 897 confirmed cases and 187,705 confirmed deaths worldwide [1] . COVID-19, the clinical manifestation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, is characterized by respiratory tract symptoms. Severe cases can involve acute respiratory distress syndrome (ARDS) and shock [2] . COVID-19 is considered mainly a respiratory tract disease, but cardiovascular complications can also occur, eventually leading to sudden deterioration [3, 4] . A large-scale study including 44,672 patients reported that cardiovascular disease was the risk factors for fatality of COVID-19 patients [5] . Intensive care unit (ICU) occupancy is very fluid, and COVID-19 patients still require better evidence-based cardiovascular treatment [6] . Inciardi et al. reported the case of a patient who recovered from the influenza-like syndrome but then developed symptoms of heart failure [3] . A recent study recommended that cardiac biomarkers should be evaluated in all hospitalized patients with confirmed COVID-19 [7] . However, there has been less concern about cardiac complications in other published studies. Data such as those from transthoracic echocardiography, cardiac magnetic resonance imaging (MRI), coronary angiography, and other examinations of cardiovascular diseases, as well as the biomarkers of cardiac injury have been less often described or are even missing.

Recent case reports have suggested that acute cardiac injury can cause cardiac dysfunction, leading to cardiogenic shock and the proclivity for malignant arrhythmia [8] . Another study reported that COVID-19 was associated with myocarditis and arrhythmia [9] . Studies have shown that cardiac injury is related to higher in-hospital mortality rate [4] and is commonly observed in severe COVID-19 cases [9] . Therefore, paying attention to the occurrence of cardiac complications in patients with COVID-19 and performing risk stratification may greatly reduce patient mortality rates, especially of those with severe disease or requiring ICU admission. To our knowledge, this is the first study to comprehensively evaluate the impact of cardiac injury and its related biomarkers on mortality and other prognosis in patients infected with SARS-CoV-2.

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement [10] . Two investigators (X.L. and Y.X.) independently conducted a comprehensive search of the relevant literature published until March 30, 2020, in the PubMed, EMBASE, Cochrane Library, MEDLINE, Chinese National Knowledge Infrastructure (CNKI), Wanfang, MedRxiv, and ChinaXiv databases. Combinations of the relevant medical subject heading (MeSH) terms, key words, and word variants of "novel coronavirus," "coronavirus disease 2019," "COVID-19," "2019-nCoV," "SARS-2-CoV," "clinical or characteristic," and "relative risk or RR" were utilized to identify all potentially relevant studies. After the elimination of duplicates, the titles and abstracts of all retrieved studies were assessed by two independent reviewers (Y.L. and N.A.) to eliminate irrelevant articles. Any disagreements were settled by consensus or by a third reviewer. Language restrictions were not applied during filtering, to maximize search sensitivity.

The inclusion criteria were as follows: (1) diagnosis of COVID-19 according to the World Health Organization interim guidance [11] and (2) (2) studies with overlapping or unusable data. The primary outcome was the incidence of death, severe disease, or ICU admission in COVID-19 patients with elevated TnI levels versus nonelevated TnI levels. The secondary outcomes were as follows: (1) incidences of elevated TnI, CK, CK-MB, LDH, or interleukin-6 (IL-6) of the non-severe disease/non-ICU versus severe disease/ICU groups; (2) incidences of elevated TnI, CK, CK-MB, LDH, or IL-6 of the survivors versus non-survivors groups; (3) TnI, CK, CK-MB, LDH, or IL-6 levels of the non-severe disease/non-ICU versus severe disease/ICU groups; (4) TnI, CK, CK-MB, LDH, or IL-6 levels of the survivors versus non-survivors groups; (5) incidence of arrhythmia (defined as newly occurring of any type) of the non-severe disease/non-ICU versus severe disease/ICU groups.

Two investigators (X.L. and X.P.) independently extracted the relevant data from the eligible studies using predesigned forms. Disagreements were resolved by consensus. If the mean and standard deviation (SD) of the laboratory findings were not directly given, we used the estimation formula based on the median, range, and sample size [12] . Definitions used for severity assessment, ICU admission, and cardiac injury were also extracted.

Two researchers (X.P. and N.A.) independently assessed the quality of the included studies, using the Newcastle-Ottawa Quality Assessment Scale [13] . Studies were defined as high quality if a score of 7 or higher was attained [13] . Potential publication bias was evaluated using the visual inspection of funnel plots and formal testing with the Egger's testing [14] .

Effect estimates are presented as relative risk (RR) or standard mean differences (SMD) with 95% confidence interval (CI). The I 2 statistic was used to quantify the heterogeneity across studies. I 2 > 50% suggested significant statistical heterogeneity [15] . In this case, a random-effects model was used considering the intraand interstudy variation. Otherwise, the pooled effect was calculated using a fixed-effects model. All analyses were performed using Stata 16.0 (StataCorp, College Station, TX, USA). Values of P < 0.05 were considered statistically significant.

We identified 1898 studies using the predefined search terms. After the removal of duplicates and filtering of titles and abstracts to exclude irrelevant articles, 67 records remained. The full text of the 67 records was reviewed; of them, 44 records were excluded for the following reasons: data not available (n = 17), literature review or letter or case report (n = 12), unrelated to relevant predictive factors (n = 13), and meta-analysis (n = 2). Finally, 23 studies were included in this metaanalysis, of which one was not written in English. The flow diagram of this study selection is shown in Fig. 1 .

The primary characteristics of the 23 included studies are listed in Table 1 , with 4631 individuals incorporated. The sample size of 16 studies was greater than 100. The definition of cardiac injury was extracted ( Table 2 ). The clinical characteristics of all included patients with COVID-19 are shown in Additional file 1: Table S1 . Overall, 16 studies reported cardiac injury biomarkers, and 4 reported arrhythmias. All the results calculated using Stata are shown in Table 3 . Fig. 3c ). Twelve studies including 2174 individuals reported the CK levels or the number of patients with above-normal CK levels. The incidence of elevated CK in the severe disease/ICU group was significantly higher than that in the nonsevere disease/non-ICU group (12.9% and 23.2%, respectively; RR 1.98, 95% CI 1.50 to 2.61, P < 0.001; I 2 = 0.0%, Fig. 4a) . The mean CK level was significantly higher in severe disease/ICU group than in the nonsevere disease/non-ICU group (SMD 0.39, 95% CI 0.11 to 0.67, P = 0.006; I 2 = 69.0%, Fig. 4b ). The proportion of patients with an elevated CK-MB level in the non-severe disease/non-ICU and severe disease/ICU groups was 14.1% and 45.7%, respectively. Patients in the severe disease/ICU admission group were at higher risk of developing an elevated CK-MB level than those in the nonsevere disease/non-ICU group (RR 3.24, 95% CI 1.66 to 6.34, P = 0.001; I 2 = 79.8%, Fig. 4c ). Of the 2532 patients from 15 studies, 29.7% of those in the non-severe disease/non-ICU group versus 60.1% of the severe disease/ ICU group had elevated LDH levels. COVID-19 patients with elevated LDH levels were at significantly increased risk of developing severe disease or requiring ICU admission (RR 2.20, 95% CI 1.55 to 3.12, P < 0.001; I 2 = 79.7%, Fig. 5a ). LDH levels were significantly higher in the severe disease/ICU admission group than in the non-severe disease/non-ICU group (SMD 1.15, 95% CI 0.61 to 1.70, P < 0.001; I 2 = 92.7%, Fig. 5b ) and in nonsurvivors than in survivors (SMD 2.86, 95% CI 0.67 to 5.06, P = 0.01; I 2 = 98.6%, Fig. 5c ).

Arrhythmia and IL-6

The incidence of arrhythmia was 3.1% in the non-severe disease/non-ICU group versus 43.8% in the severe disease/ICU group. Patients with newly occurring arrhythmias were at a higher risk of developing severe disease or requiring ICU admission (RR 13.09, 95% CI 7.00 to 24.47, P < 0.001; I 2 = 42.0%, Fig. 6a ). IL-6 levels were significantly higher in the severe disease/ICU group than in the non-severe disease/non-ICU group, as well as in non-survivors than in survivors (SMD 0.54, 95% CI 0.27 to 0.81, P < 0.001; I 2 = 0.0%, Fig. 6b ; SMD 1.28, 95% CI 1.00 to 1.57, P < 0.001; I 2 = 13.7%, Fig. 6c , respectively).

This systematic review and meta-analysis of 23 highquality retrospective studies systematically evaluated the risk of severe disease, ICU admission, or death associated with COVID-19-related cardiac injury performance. Our findings are as follows: (1) COVID-19 patients with elevated TnI levels are at significantly higher risk of developing severe disease, requiring ICU admission, or death; (2) elevated CK, CK-MB, LDH, and IL-6 levels and emerging arrhythmia are associated with the development of severe disease or requirement for ICU admission; and (3) mortality rates are significantly higher among patients with elevated LDH and IL-6 levels.

Cardiac injury was defined as a serum cardiac biomarker level (e.g., troponin I) above the 99th percentile upper reference limit or new abnormalities seen on electrocardiography (ECG) and echocardiography [2] . CK, CK-MB, and LDH are also indicators associated with cardiac injury [37, 38 ]. An elevated cardiac TnI level has high specificity for cardiac injury and is a preferred biomarker of cardiac injury. Overall, in 8 studies including 1028 patients, the rates of elevated TnI or TnT in the nonsevere disease/non-ICU admission group and severe disease/ICU admission group were 2.3% and 36.9%, respectively; in the total population, elevated TnI or TnT BNP B-type natriuretic peptide, CK creatinine kinase, CK-MB creatinine kinase-myocardial band, ICU intensive care unit, LDH lactate dehydrogenase, IL-6 interleukin-6, n number, NA not available, NT-proBNP N-terminal pro-B-type natriuretic peptide, RR risk ratios, SMD standard mean occurred at a rate of 11.9%. Our analysis suggests that COVID-19 patients with elevated TnI levels are at higher risk of developing severe disease, requiring ICU admission, and death. Two studies from Wuhan (one with 416 cases, another with 187 cases) reported higher mortality among patients with cardiac injury than among those without (51.2% vs. 4.5%; P < 0.001; 59.6% vs. 8.9%, P < 0.001, respectively) [4, 36] . Patients with cardiac injury had higher serum concentrations of NT-proBNP than those without cardiac injury [36, 39] . Patients with cardiac injury more commonly developed ARDS, were more likely to have ventricular tachycardia (VT) or ventricular fibrillation (VF), and had higher mortality rates than those without VT or VF [36, 39] . TnI has great prognostic significance for patients with COVID-19 as well as those with other influenza virus infections. In a study of 75 inpatients with SARS, acute myocardial infarction was the cause of 2 of 5 deaths [40] . Elevated TnI levels are also common in infections caused by other influenza virus subtypes [41] [42] [43] [44] [45] . TnI may play an important role in predicting the acute or long-term risk of influenza virus infection. Other biomarkers closely related to cardiac injury, such as CK, CK-MB, and LDH, were also selected in the meta-analysis. Our analysis showed that those with elevated CK, CK-MB, and LDH were at a higher risk of developing severe disease or requiring ICU admission. The LDH level had a predictive value for death. Previous studies suggested that CK at ICU admission serves can be used as a biomarker of the severity of 2009 pandemic influenza A (pH1N1) infection [46] .

Elevated TnI and CK-MB levels indicate cardiac injury such as viral myocarditis or myocardial infarction as well as multiple organ injury [47] . Initial reports showed that the possible pattern of myocardial injury is the early presentation of primary cardiovascular symptoms, as well as changes on echocardiography and ECG [3, 6, [48] [49] [50] . Stress cardiomyopathy, supply demand mismatch (type II myocardial infarction), and myocarditis, sometimes similar to ST-segment elevation myocardial infarction, are all possible mechanisms [3, 6, 49] . In a study describing a single case without a history of cardiovascular disease, the patient had myocardial injury, and diffuse edema was seen on cardiac MRI [3] . Twelve lead ECG showed minimal diffuse ST-segment elevation and an ST-segment depression with T-wave inversion of lead V1 and aVR. Even in the absence of respiratory tract or infection symptoms, SARS-CoV-2 infection may cause cardiac involvement. However, it is a pity that an endomyocardial biopsy was not performed; thus, there was no histological evidence [3] . Cardiac injury is an important prognostic factor for COVID-19. It is rational to presume that the virus affects the myocardium, and once patients develop severe pneumonia, cardiac injury or dysfunction is more likely to occur, leading to deterioration. In a study of critically ill patients, including 21 who had SARS-CoV-2 infection in the USA, the incidence of cardiomyopathy was high (n = 7 [33%]) [51] . In a patient without fever and respiratory symptoms, the initial ECG showed diffuse ST elevations and an admission TnI level of 7.9 ng/mL, but angiography demonstrated non-obstructive coronary artery disease. After Fig. 3 Forest plots comparing of the proportion of patients with elevated troponin I or troponin T levels in the severe disease/ICU group and in the non-severe disease/non-ICU group (a), the troponin I levels in the severe disease/ICU group and in the non-severe disease/non-ICU group (b), and the proportion of patients with elevated troponin I or troponin T levels in the survivors and non-survivors groups (c). ICU, intensive care unit; RR, risk ratios; SMD, standard mean treatment, this patient improved in the short term, but the long-term effects of myocardial injury remain to be determined [8] .

The etiology of cardiac dysfunction may be multifactorial and related to infective myocarditis and/or ischemia. Pathological findings suggested a few interstitial Fig. 4 Forest plots comparing of the proportion of patients with elevated creatinine kinase levels in the severe disease/ICU group and in the non-severe disease/non-ICU group (a), the creatinine kinase levels in the severe disease/ICU group and in the non-severe disease/non-ICU group (b), and the proportion of patients with elevated creatinine kinase-myocardial band levels in the severe disease/ICU group and in the non-severe disease/non-ICU group (c). ICU, intensive care unit; RR, risk ratios; SMD, standard mean mononuclear inflammatory infiltrates in the myocardial interstitial [52] . Viral invasion may cause direct cardiac injury, and COVID-19-induced cytokine storm may also have toxic effects on the myocardium [53] . Cytokine storm may play a role in the development of ARDS and fulminant myocarditis. In our analysis, 3 studies reported the laboratory findings of IL-6 levels in 526 patients. IL-6 levels were significantly higher in the severe disease/ Fig. 5 Forest plots comparing of the proportion of patients with elevated lactate dehydrogenase levels in the severe disease/ICU group and in the non-severe disease/non-ICU group (a), the lactate dehydrogenase levels in the severe disease/ICU group and in the non-severe disease/non-ICU group (b), and the lactate dehydrogenase levels in the survivors and non-survivor groups (c). ICU, intensive care unit; RR, risk ratios; SMD, standard mean Fig. 6 Forest plots comparing of the risk of developing to severe disease or requiring ICU admission among patients with or without newly occurring arrhythmias (a), the interleukin-6 levels in the severe disease/ICU group (b), and in the non-severe disease/non-ICU group and the interleukin-6 levels in the survivors and non-survivors groups (c). ICU, intensive care unit; RR, risk ratios; SMD, standard mean ICU groups than non-severe disease/non-ICU groups, as well as in non-survivors than in survivors. Cardiac involvement reportedly occurred a few days after the influenza syndrome, suggesting the mechanisms of a potential myocyte dissemination of the virus activating the immune system, eventually leading to the onset of heart failure [3] . A study reported that, compared to survivors, non-survivors had increased concentrations of Creactive protein, decreased lymphocyte counts, and significantly reduced numbers of CD3 + CD8 + T cells, resulting in an immune response [54] . Anti-IL-6, as a drug targeting cytokine pathway and based on its mechanism of action, has potential benefits in COVID-19related ARDS and pneumonia [55] .

Our analysis also found that the patients with emerging arrhythmia are at a higher risk of developing severe disease or requiring ICU admission. In a study of 41 patients with COVID-19, atrial fibrillation occurred in 2 of 3 severe and critical patients with tachycardia, with a peak heart rate of 160 bpm [22] . Newly occurring arrhythmias are often closely related to cardiac injury. The incidence of ventricular arrhythmias (VT/VF) among 187 patients with COVID-19 was 5.9%, primarily affecting those with elevated cardiac troponin levels [36] . One study reported that 5 of 6 acute myocardial injury patients had more than two kinds of ECG abnormalities, including ST-T/Q curve abnormality, atrioventricular block, and arrhythmia [28] . Severe pneumonia increases the resistance of the pulmonary circulation, increasing the pressure of the right atrium, and leading to atrial tachyarrhythmia. Antiviral drugs such as hydroxychloroquine may also prolong the QT interval. Alternatively, the virus directly damages the myocardium and the cardiac conduction system, causing multiple ventricular premature and atrioventricular block. More attention is needed on arrhythmia among severe disease/ICU admission COVID-19 patients. However, in the studies reviewed here, ECG or echocardiography was rarely performed and the occurrence of arrhythmia was rarely reported.

This meta-analysis included the largest sample size and is the first to analyze the correlation of cardiac injury biomarkers and arrhythmia with mortality and other prognosis. Our systematic review and meta-analysis indicate that patients with elevated TnI (TnT) levels are at significantly higher risk of developing severe disease, requiring ICU admission, or death. Our analysis also reveals that patients with elevated CK, CK-MB, and LDH levels and emerging arrhythmia were at a higher risk of developing severe disease, requiring ICU admission. LDH levels also have predictive value for death. Therefore, we strongly recommend the close monitoring of cardiac injury-related biomarkers in COVID-19 patients, especially during the acute disease phase.

The current clinical attention given to cardiac injury may be insufficient, and the strong infection of the virus makes cardiovascular examinations such as MRI, echocardiography, and coronary angiography difficult to perform [56] . The evaluation of cardiac injury biomarkers combined with cardiac examinations may help better assessments of the condition. There are few reports on cardiac injury in COVID-19 patients, and a large amount of evidence is still needed to make the necessary risk predictions and stratifications. The present results provide some evidence for COVID-19 treatment guidelines. In the future, it well be necessary to strengthen the monitoring of cardiac injury biomarkers, combined with echocardiography [57] , ECG, MRI, and other cardiac examinations, in patients with severe SARS-CoV-2 infection. When circulation support is needed in severe COVID-19 cases, the use of an intra-aortic balloon pump or extracorporeal membrane oxygenation may be considered [8] .

COVID-19) Pandemic. Accessed 25

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan

Clinical determinants for fatality of 44,672 patients with COVID-19

COVID-19 pandemic-some cardiovascular considerations from the trench

A care pathway for the cardiovascular complications of COVID-19: insights from an institutional response

The variety of cardiovascular presentations of COVID-19

Potential effects of coronaviruses on the cardiovascular system: a review

The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance

Estimating the mean and variance from the median, range, and the size of a sample

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Publication and related bias in metaanalysis: power of statistical tests and prevalence in the literature

Prior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19)

Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study

Clinical characteristics of coronavirus disease 2019 in China

Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia

Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019

Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing

Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study

Clinical characteristics of patients with severe pneumonia caused by the 2019 novel coronavirus in Wuhan, China

Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19)

Acute myocardial injury of patients with coronavirus disease 2019

Clinical findings in critical ill patients infected with SARS-Cov-2 in Guangdong Province, China: a multi-center, retrospective, observational study

Clinical features and outcomes of 2019 novel coronavirus-infected patients with cardiac injury

Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV

Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China

The potential role of IL-6 in monitoring severe case of coronavirus disease 2019

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Creatine kinase myocardial band -a biomarker to assess prognostically relevant periprocedural myocardial infarction

Lactic dehydrogenase isoenzyme determination in the diagnosis of acute myocardial infarction

Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Echocardiographic manifestations of pandemic 2009 (H1N1) influenza a virus infection

pandemic H1N1-associated myocarditis in a previously healthy adult

Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care

Influenza myocarditis and myositis: case presentation and review of the literature

The Prevalence and findings of subclinical influenza-associated cardiac abnormalities among Japanese Patients

Elevation of creatine kinase is associated with worse outcomes in 2009 pH1N1 influenza A infection

Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity

Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

First case of COVID-19 complicated with fulminant myocarditis: a case report and insights

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Coronavirus disease 2019 (COVID-19) and cardiovascular disease

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients

Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC's interventional council and SCAI

Using echocardiography to guide the treatment of novel coronavirus pneumonia

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

None. Received: 30 April 2020 Accepted: 15 July 2020

Supplementary information accompanies this paper at https://doi.org/10. 1186/s13054-020-03183-z.Additional file 1: Table S1 . Clinical characteristics of patients with COVID-19. 

All the data supporting the conclusions of this article are included within the article.

This article is meta-analysis and does not require ethics committee approval or a consent statement.

All authors have agreed to the publication of this manuscript.

The authors declare that they have no competing interests.